Crinetics Pharmaceuticals Q2 2024 GAAP EPS $(0.94) Misses $(0.85) Estimate, Sales $399.000K Miss $510.000K Estimate
Author: Benzinga Newsdesk | August 08, 2024 04:39pm
Crinetics Pharmaceuticals (NASDAQ:
CRNX) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.85) by 10.59 percent. This is unchanged from the same period last year. The company reported quarterly sales of $399.000 thousand which missed the analyst consensus estimate of $510.000 thousand by 21.76 percent. This is a 59.62 percent decrease over sales of $988.000 thousand the same period last year.
Posted In: CRNX